Supernus Pharmaceuticals (SUPN) Non Operating Income (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Non Operating Income data on file, last reported at $2.0 million in Q4 2025.

• Non Operating Income for Q4 2025 came in at $2.0 million, down 59.35% year-over-year; the trailing twelve-month figure through Dec 2025 was $13.3 million (down 18.21% YoY), and the FY2025 annual result was $13.3 million, down 18.21% from the prior year.
• Non Operating Income fell to $2.0 million in Q4 2025 per SUPN's latest filing, from $2.3 million in the prior quarter.
• Over five years, Non Operating Income peaked at $14.7 million in Q1 2022 and troughed at -$21.5 million in Q4 2021.
• A 5-year average of $1.8 million and a median of $2.3 million in 2021 frame the typical range for Non Operating Income.
• On a YoY basis, Non Operating Income climbed as much as 17227.27% in 2021 and fell as far as 273.16% in 2021.
• A 5-year view of Non Operating Income shows it stood at -$21.5 million in 2021, then jumped by 111.14% to $2.4 million in 2022, then sank by 117.88% to -$429000.0 in 2023, then soared by 1260.14% to $5.0 million in 2024, then plunged by 59.35% to $2.0 million in 2025.
• Business Quant data shows SUPN's Non Operating Income at $2.0 million in Q4 2025, $2.3 million in Q3 2025, and $4.5 million in Q2 2025.